What is the recommended intravenous (IV) dose of acetylcysteine (N-acetylcysteine) for treating liver failure due to acetaminophen (paracetamol) toxicity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For acetaminophen toxicity causing liver failure, the recommended N-acetylcysteine (NAC) intravenous regimen is a loading dose of 150 mg/kg administered over 15 minutes, followed by 50 mg/kg over 4 hours, and then 100 mg/kg over 16 hours, as this protocol has been shown to be effective and safe in numerous controlled trials 1.

Key Considerations

  • The treatment should be initiated as soon as possible after acetaminophen ingestion, ideally within 8-10 hours for best outcomes, though it may still provide benefit when started later 1.
  • NAC should be diluted in 5% dextrose solution rather than normal saline.
  • For patients weighing over 100 kg, some clinicians cap the dose calculation at 100 kg to avoid excessive dosing.
  • The mechanism of action involves NAC replenishing glutathione stores, which are depleted during acetaminophen metabolism, thereby preventing the toxic metabolite NAPQI from causing hepatocellular damage.
  • Treatment duration may be extended beyond 21 hours if liver enzymes remain elevated or the patient shows signs of ongoing liver injury.
  • Common side effects include nausea, vomiting, and anaphylactoid reactions, particularly during the loading dose, which may require slowing the infusion rate.

Recent Guidelines

  • The American Gastroenterological Association Institute guidelines support the use of NAC in patients with ALF related to acetaminophen, with a strong recommendation 1.
  • The management of liver failure in general intensive care units also recommends the initiation of N-acetylcysteine therapy without waiting for, and regardless of, the results of serum acetaminophen determinations, with a strong agreement 1.

Administration

  • NAC may be given orally (140 mg/kg by mouth or nasogastric tube diluted to 5% solution, followed by 70 mg/kg by mouth q 4 h 17 doses) or intravenously, with the intravenous route being preferred in patients with ALF due to potential issues with oral administration 1.
  • Allergic reactions may be successfully treated with discontinuation, antihistamines, and epinephrine for bronchospasm.

From the Research

Acetylcysteine Drip Dose for Liver Failure due to Acetaminophen Toxicity

  • The standard treatment for acetaminophen-induced liver injury is N-acetylcysteine, which is a known scavenger of reactive oxygen species (ROS) 2.
  • Acetaminophen overdose has a 66% chance of recovery with early N-acetylcysteine treatment and supportive care 3.
  • The American Association for the Study of Liver Diseases (AASLD) 2011 guideline suggested that N-acetylcysteine could improve spontaneous survival when given during early encephalopathy stages for patients with non-paracetamol-related acute liver failure 4.
  • However, the available evidence is inconclusive regarding the effect of N-acetylcysteine compared with placebo or no N-acetylcysteine, as an adjunct to usual care, on mortality or transplant rate in non-paracetamol-induced acute liver failure 4.
  • N-acetylcysteine remains the standard of care in the setting of acetaminophen toxicity 5.

Dosage and Administration

  • The exact drip dose of acetylcysteine for liver failure due to acetaminophen toxicity is not specified in the provided studies.
  • However, it is mentioned that N-acetylcysteine is given at a dose of 100 mg/kg in an experimental study on rats 6.
  • Further research is needed to determine the optimal dose and duration of N-acetylcysteine treatment for acetaminophen-induced liver injury.

Alternative Treatments

  • Leuco-methylene blue (LMB) has been shown to have a protective effect against acetaminophen-induced liver injury in an experimental study on rats 6.
  • LMB significantly reduced serum levels of liver enzymes and increased the expression of genes involved in mitochondrial biogenesis and antioxidant defense.
  • However, more research is needed to confirm the efficacy and safety of LMB as a treatment for acetaminophen-induced liver injury in humans.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.